Solasta Ventures focuses on investing in life sciences companies, particularly those developing therapeutics and technology that can transform patient care in the U.S. and globally. Their strategy involves identifying strong management teams and leveraging their South Korean network to foster potential US-Korea synergies and collaborations with global pharmaceutical companies.
40% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (80% of deals). Average disclosed round size is $64.0M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Axonis Therapeutics | Series A | $115M | Oct 2024 |
 Prime Roots | Series B | $30M | May 2023 |
 Soul Machines | Series B | $70M | Feb 2022 |
 HotSpot Therapeutics, Inc. | Series B | $65M | May 2020 |
 Exo | Series B | $40M | — |
Top Co-Investors
Sofinnova Partners2 shared
MRL Ventures Fund2 shared
Cormorant Asset Management1 shared
venBio1 shared
Perceptive Advisors1 shared
SC Ventures1 shared
Alexandria Venture Investments1 shared
Tekla Capital Management1 shared
Atlas Venture1 shared
True Ventures1 shared
Prosus Ventures1 shared
Top Tier Capital Partners1 shared
Diamond Edge Ventures1 shared
Monde Nissin1 shared
Alumni Ventures Group1 shared
Gaingels1 shared
Meach Cove Capital1 shared
The House Fund1 shared
Hyphen Capital1 shared
SoftBank Vision Fund1 shared
Last updated: 16 April 2026